Dexamethasone intravitreal implant for the treatment of noninfectious uveitis

Rebecca S Hunter, Ann-Marie Lobo Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA Abstract: Uveitis can be a sight-threatening eye disease with significant morbidity. Corticosteroids remain the mainstay of treatment of uveitis and provide an e...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hunter RS, Lobo AM
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/f3cb4482fa3740d89096cf1e0f77ec81
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f3cb4482fa3740d89096cf1e0f77ec81
record_format	dspace
spelling	oai:doaj.org-article:f3cb4482fa3740d89096cf1e0f77ec812021-12-02T02:12:18ZDexamethasone intravitreal implant for the treatment of noninfectious uveitis1177-54671177-5483https://doaj.org/article/f3cb4482fa3740d89096cf1e0f77ec812011-11-01T00:00:00Zhttp://www.dovepress.com/dexamethasone-intravitreal-implant-for-the-treatment-of-noninfectious--a8640https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Rebecca S Hunter, Ann-Marie Lobo Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA Abstract: Uveitis can be a sight-threatening eye disease with significant morbidity. Corticosteroids remain the mainstay of treatment of uveitis and provide an effective treatment against ocular inflammation. However, the various modes available for corticosteroid drug delivery can carry significant ocular and systemic side effects which can limit their use in the treatment of uveitis. In an effort to avoid the damage to ocular structures that can ensue with recurrent episodes of ocular inflammation, the side effects associated with systemic steroids, and the need for repeated administration of both topical and locally injected corticosteroids, sustained-release intraocular corticosteroid implants have been developed. The dexamethasone (DEX) drug delivery system (Ozurdex&reg;; Allergan Inc, Irvine, CA), is a biodegradable intravitreal implant. This implant has been shown to be effective in the treatment of macular edema and noninfectious posterior uveitis and has been approved by the FDA for these entities. This review will highlight the current methods available for corticosteroid delivery to the eye with a particular emphasis on the DEX intravitreal implant and the evidence currently available for its use in noninfectious uveitis. Keywords: dexamethasone implant, uveitis, macular edema, corticosteroidsHunter RSLobo AMDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2011, Iss default, Pp 1613-1621 (2011)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Hunter RS Lobo AM Dexamethasone intravitreal implant for the treatment of noninfectious uveitis
description	Rebecca S Hunter, Ann-Marie Lobo Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA Abstract: Uveitis can be a sight-threatening eye disease with significant morbidity. Corticosteroids remain the mainstay of treatment of uveitis and provide an effective treatment against ocular inflammation. However, the various modes available for corticosteroid drug delivery can carry significant ocular and systemic side effects which can limit their use in the treatment of uveitis. In an effort to avoid the damage to ocular structures that can ensue with recurrent episodes of ocular inflammation, the side effects associated with systemic steroids, and the need for repeated administration of both topical and locally injected corticosteroids, sustained-release intraocular corticosteroid implants have been developed. The dexamethasone (DEX) drug delivery system (Ozurdex&reg;; Allergan Inc, Irvine, CA), is a biodegradable intravitreal implant. This implant has been shown to be effective in the treatment of macular edema and noninfectious posterior uveitis and has been approved by the FDA for these entities. This review will highlight the current methods available for corticosteroid delivery to the eye with a particular emphasis on the DEX intravitreal implant and the evidence currently available for its use in noninfectious uveitis. Keywords: dexamethasone implant, uveitis, macular edema, corticosteroids
format	article
author	Hunter RS Lobo AM
author_facet	Hunter RS Lobo AM
author_sort	Hunter RS
title	Dexamethasone intravitreal implant for the treatment of noninfectious uveitis
title_short	Dexamethasone intravitreal implant for the treatment of noninfectious uveitis
title_full	Dexamethasone intravitreal implant for the treatment of noninfectious uveitis
title_fullStr	Dexamethasone intravitreal implant for the treatment of noninfectious uveitis
title_full_unstemmed	Dexamethasone intravitreal implant for the treatment of noninfectious uveitis
title_sort	dexamethasone intravitreal implant for the treatment of noninfectious uveitis
publisher	Dove Medical Press
publishDate	2011
url	https://doaj.org/article/f3cb4482fa3740d89096cf1e0f77ec81
work_keys_str_mv	AT hunterrs dexamethasoneintravitrealimplantforthetreatmentofnoninfectiousuveitis AT loboam dexamethasoneintravitrealimplantforthetreatmentofnoninfectiousuveitis
_version_	1718402629683380224

Dexamethasone intravitreal implant for the treatment of noninfectious uveitis

Ejemplares similares